Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,669 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral placebo capsules Clear all
Not yet recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

NCT07723963
View directory record Official record
Conditions
Juvenile Myoclonic Epilepsy
Interventions
JZP926 capsule, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

NCT00890825
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AZD6244, docetaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Determine the Bioavailability of Oral Beta-Aminoisobutyric Acid (BAIBA) Ingestion

NCT05328271
View directory record Official record
Conditions
Absorption; Chemicals
Interventions
Beta-Aminoisobutyric Acid
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 2 Interventional

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

NCT00722358
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Orlando, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Spironolactone Therapy In Young Women With NASH

NCT03576755
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Spironolactone 100mg, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 26, 2026, 10:17 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

NCT02162758
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Dexlansoprazole, Dexlansoprazole Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Jacksonville, Florida • Chapel Hill, North Carolina • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285
View directory record Official record
Conditions
Obesity
Interventions
Galantamine, Placebo Oral Capsule, Intralipid, Heparin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

NCT00724048
View directory record Official record
Conditions
Huntington Disease
Interventions
ACR16, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • San Diego, California • Littleton, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 26, 2026, 10:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

NCT03736447
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 3 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Little Rock, Arkansas • Mountain View, California • Rolling Hills Estates, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-68179280 in Healthy Participants

NCT04844463
View directory record Official record
Conditions
Healthy
Interventions
JNJ-68179280, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 26, 2026, 10:17 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ongoing Lung Decline With Age Intensified Response

NCT07676435
View directory record Official record
Conditions
Age-Related Lung Function Decline
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

NCT03265288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

Trial of AD036 in Obstructive Sleep Apnea

NCT03845023
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD036 Dose 1, AD036 Dose 2, AD036 Dose 3, Placebo
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Glendale, Arizona • Little Rock, Arkansas • Redwood City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

NCT01370317
View directory record Official record
Conditions
Asthma
Interventions
MK-1029, Placebo for MK-1029
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Costa Mesa, California • Rolling Hills Estates, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

NCT01850524
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Placebo, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

NCT00489255
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tigan®, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 3 Interventional

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526
View directory record Official record
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

NCT03551691
View directory record Official record
Conditions
Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Omeprazole 20mg Capsule, Placebo oral capsule
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 26, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01710046
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
(CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 26, 2026, 10:17 AM EDT